APOB and type 2 diabetes mellitus: In 2013, the use of colesevelam (3.75 g/day) in 176 T2D patients for 24 weeks was shown to reduce total cholesterol, LDL-C and apoB by −5.1%, −11.2% and −6.5%, respectively, compared to 181 patients treated with placebo [65].